



(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 35/04 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2010/058906

(22) International Filing Date:

3 December 2010 (03.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/266,848 4 December 2009 (04.12.2009) US

(71) Applicant (for all designated States except AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, US): **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US).

(71) Applicant (for AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR only): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AGRESTA, Samuel** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **KLENCKE, Barbara** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US).

(74) Agents: **PASQUALONE, Danielle, M.** et al.; Genentech, Inc., 1 DNA Way, MS-49, South San Francisco, California 94080-4990 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

19 April 2012

(54) Title: METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1




FIG. 4

(57) Abstract: Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab.

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2010/058906

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K39/395 A61P35/00 A61P35/04
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BURRIS H ET AL: "5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 7, no. 2, 1 September 2009 (2009-09-01), pages 266-267, XP026689718, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(09)70912-7 [retrieved on 2009-09-01]	1-6,9-12
Y	the whole document ----- -/--	7,8,13, 14

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

15 February 2012

Date of mailing of the international search report

28/02/2012

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Ganschow, Silke

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2010/058906

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2009/117277 A2 (GENENTECH INC [US]; BERRY LEANNE [US]; PHILLIPS GAIL LEWIS [US]; SLIWK) 24 September 2009 (2009-09-24) paragraph [00289] - paragraph [00290] -----	7,8,13, 14
A	Genentech: "View of NCT00679211 on 2009_03_04", Internet 4 March 2009 (2009-03-04), XP002669560, Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCT00679211/2009_03_04 [retrieved on 2012-02-15] Official title, Inclusion Criteria -----	1-14
T	KROP I ET AL: "A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 69, no. 24, Suppl, 15 December 2009 (2009-12-15), XP009156504, ISSN: 0008-5472 the whole document -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2010/058906

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009117277 A2	24-09-2009	AR 070865 A1	12-05-2010
		AU 2009225877 A1	24-09-2009
		CA 2716592 A1	24-09-2009
		CN 102036660 A	27-04-2011
		CR 11678 A	13-12-2010
		EP 2254571 A2	01-12-2010
		JP 2012500180 A	05-01-2012
		KR 20100129318 A	08-12-2010
		TW 200942261 A	16-10-2009
		WO 2009117277 A2	24-09-2009
